Evidence map›Paper›PMID 36434110›Full record

ArticleScientific reports2022

Analysis of serum circulating MicroRNAs level in Malaysian patients with gestational diabetes mellitus.

Sajad Jamalpour, Shamsul Mohd Zain, Reza Vazifehmand, Zahurin Mohamed, Yuh Fen Pung, Hesam Kamyab, Siti Zawiah Omar

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sajad JamalpourThe Pharmacogenomics Laboratory, Department of Pharmacology, Universiti Malaya, Kuala Lumpur, Malaysia. sajad.jamalpour@gmail.com.
Shamsul Mohd ZainThe Pharmacogenomics Laboratory, Department of Pharmacology, Universiti Malaya, Kuala Lumpur, Malaysia.
Reza VazifehmandDepartment of Bioscience, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Kuala Lumpur, Malaysia.
Zahurin MohamedThe Pharmacogenomics Laboratory, Department of Pharmacology, Universiti Malaya, Kuala Lumpur, Malaysia.
Yuh Fen PungDivision of Biomedical Science, School of Pharmacy, University of Nottingham Malaysia, Selangor, Malaysia.
Hesam KamyabMalaysia-Japan International Institute of Technology Universiti Teknologi Malaysia, Jalan Sultan Yahya Petra, 54100, Kuala Lumpur, Malaysia.
Siti Zawiah OmarDepartment of Obstetrics & Gynaecology, University of Malaya, Kuala Lumpur, Malaysia. szawiah@um.edu.my.
University of Malaya · MYUniversiti Putra Malaysia · MYUniversity of Nottingham Malaysia Campus · MYUniversity of Technology Malaysia · MY

Funding

Zahurin Mohamed UM.C/625/1/HIR/ MOHE/ MED/28)
6 · The paper itself

Abstract

Gestational diabetes mellitus (GDM) is a severe global issue that requires immediate attention. MicroRNA expression abnormalities are possibly disease-specific and may contribute to GDM pathological processes. To date, there is limited data on miRNA profiling in GDM, especially that involves a longitudinal study. Here, we performed miRNA expression profiling in the entire duration of pregnancy (during pregnancy until parturition and postpartum) using a miRNA- polymerase chain reaction array (miRNA-PCRArray) and in-silico analysis to identify unique miRNAs expression and their anticipated target genes in Malay maternal serum. MiRNA expression levels and their unique potential as biomarkers were explored in this work. In GDM patients, the expression levels of hsa-miR-193a, hsa-miR-21, hsa-miR-23a, and hsa-miR-361 were significantly increased, but miR-130a was significantly downregulated. The area under the curve (AUC) and receiver operating characteristic (ROC) curve study demonstrated that hsa-miR-193a (AUC = 0.89060 ± 04,470, P = 0.0001), hsa-miR-21 (AUC = 0.89500 ± 04,411, P = 0.0001), and miR-130a (AUC = 0.6939 ± 0.05845, P = 0.0025) had potential biomarker features in GDM. In-silico analysis also revealed that KLF (Kruppel-Like family of transcription factor), ZNF25 (Zinc finger protein 25), AFF4 (ALF transcription elongation factor 4), C1orf143 (long intergenic non-protein coding RNA 2869), SRSF2 (serine and arginine rich splicing factor 2), and ZNF655 (Zinc finger protein 655) were prominent genes targeted by the common nodes of miR23a, miR130, miR193a, miR21, and miR361.Our findings suggest that circulating microRNAs in the first trimester has the potential for GDM screening in the Malay population.

Indexed as

Circulating MicroRNADiabetes, GestationalMicroRNAsBiomarkersFemaleHumansKruppel-Like Transcription FactorsLongitudinal StudiesPregnancyTranscriptional Elongation FactorsAFF4 protein, humanBiomarkersCirculating MicroRNAKruppel-Like Transcription FactorsMicroRNAsMIRN21 microRNA, humanTranscriptional Elongation FactorsZNF655 protein, human

Identifiers

PMID36434110
PMCPMC9700700
OpenAlexW4310057549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.